NASDAQ:RXST RxSight (RXST) Stock Price, News & Analysis $26.12 +0.90 (+3.57%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$21.00 -5.12 (-19.60%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About RxSight Stock (NASDAQ:RXST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RxSight alerts:Sign Up Key Stats Today's Range$24.81▼$26.3850-Day Range$24.37▼$34.2652-Week Range$21.00▼$66.54Volume736,972 shsAverage Volume551,586 shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice Target$49.33Consensus RatingModerate Buy Company OverviewRxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Read More… Remove Ads RxSight Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreRXST MarketRank™: RxSight scored higher than 72% of companies evaluated by MarketBeat, and ranked 310th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRxSight has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRxSight has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about RxSight's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($0.70) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -31.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -31.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about RxSight's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.40% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in RxSight has recently increased by 8.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.40% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in RxSight has recently increased by 8.81%, indicating that investor sentiment is decreasing significantly. News and Social Media3.9 / 5News Sentiment1.11 News SentimentRxSight has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for RxSight this week, compared to 5 articles on an average week.Search Interest5 people have searched for RXST on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows4 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have sold 541.44% more of their company's stock than they have bought. Specifically, they have bought $44,993.00 in company stock and sold $288,602.00 in company stock.Percentage Held by InsidersOnly 9.36% of the stock of RxSight is held by insiders.Percentage Held by Institutions78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RxSight's insider trading history. Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Stock News HeadlinesRxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 GuidanceApril 2 at 8:00 PM | globenewswire.comBofA sees Bausch + Lomb IOL recall news as positive for RxSightMarch 27, 2025 | msn.comCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.April 3, 2025 | Paradigm Press (Ad)RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 25, 2025 | globenewswire.comBank of America Cuts RxSight (NASDAQ:RXST) Price Target to $36.00March 24, 2025 | americanbankingnews.comRxSight price target lowered to $36 from $60 at BofAMarch 21, 2025 | markets.businessinsider.comThe Analyst Verdict: RxSight In The Eyes Of 9 ExpertsMarch 21, 2025 | nasdaq.comRxSight price target lowered to $28 from $33 at StifelMarch 20, 2025 | markets.businessinsider.comSee More Headlines RXST Stock Analysis - Frequently Asked Questions How have RXST shares performed this year? RxSight's stock was trading at $34.38 at the beginning of 2025. Since then, RXST shares have decreased by 24.0% and is now trading at $26.12. View the best growth stocks for 2025 here. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) issued its quarterly earnings results on Tuesday, February, 25th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.10 by $0.25. The business had revenue of $40.21 million for the quarter, compared to analysts' expectations of $40.23 million. RxSight had a negative trailing twelve-month return on equity of 14.00% and a negative net margin of 23.92%. When did RxSight IPO? RxSight (RXST) raised $125 million in an IPO on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RxSight own? Based on aggregate information from My MarketBeat watchlists, some other companies that RxSight investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), ServiceNow (NOW), Arista Networks (ANET) and Disc Medicine (IRON). Company Calendar Last Earnings2/25/2025Today4/03/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Ophthalmic goods Sub-IndustryMedical Equipment Current SymbolNASDAQ:RXST CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$49.33 High Stock Price Target$73.00 Low Stock Price Target$28.00 Potential Upside/Downside+88.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,610,000.00 Net Margins-23.92% Pretax Margin-23.91% Return on Equity-14.00% Return on Assets-12.51% Debt Debt-to-Equity RatioN/A Current Ratio12.67 Quick Ratio11.71 Sales & Book Value Annual Sales$139.93 million Price / Sales7.56 Cash FlowN/A Price / Cash FlowN/A Book Value$4.47 per share Price / Book5.84Miscellaneous Outstanding Shares40,491,000Free Float36,532,000Market Cap$1.06 billion OptionableOptionable Beta1.22 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RXST) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.